Weight Loss Injections vs Surgery: What the Evidence Actually Shows

What the trial data says about injections (and where surgery still leads

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and found that tirzepatide at its highest dose produced around 20–21% average weight loss over 72 weeks) a figure that genuinely surprised researchers expecting a larger gap with surgery. The STEP 1 trial for semaglutide 2.4mg (Wegovy) reported around 15% average reduction over 68 weeks. Bariatric procedures, by comparison, typically produce 25–35% excess weight loss depending on the type (gastric bypass tends to sit at the higher end; gastric sleeve somewhat lower), and the effects are largely sustained without ongoing medication.

So the honest picture is this: injections have closed the gap considerably, but surgery still tends to produce greater total weight loss in head-to-head comparisons. Where injections increasingly outperform surgery is reversibility — stop the medicine and the pharmacological effect reverses, which is either a reassurance or a limitation depending on how you look at it. Weight loss injections also carry none of the procedural risks of general anaesthesia and abdominal surgery, which matter most to people with complex health conditions.

One misconception worth clearing up gently: some people assume surgery is a permanent fix that removes the need for any ongoing effort. In reality, post-surgical patients require lifelong dietary adjustment, supplementation and follow-up. The work looks different, but it doesn't disappear.

Sources: SURMOUNT-1, NEJM; NICE TA1026 (tirzepatide); NICE TA875 (semaglutide).

Who the licensed injections are intended for (and where surgery fits instead

Licensed GLP-1 and GIP injections in the UK) currently Mounjaro (tirzepatide) and Wegovy (semaglutide), are approved for adults with a BMI of 30 or above, or from 27 with at least one weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. The cost of treatment varies by dose and provider; what it should always include is a proper clinical assessment.

Bariatric surgery in the NHS typically requires a BMI above 40, or above 35 with significant comorbidities, alongside documented previous attempts at non-surgical weight management. Private surgery is accessible at lower thresholds but still involves a multidisciplinary assessment. People with a BMI in the 30–40 range who don't meet surgical criteria, or who prefer to avoid an operation, are often the group injections serve best. Those with a BMI above 50 or with severe metabolic disease may still find surgery produces outcomes that injections cannot match.

It's also worth knowing that the two approaches aren't always mutually exclusive. Some people use GLP-1 medicines to reduce weight before surgery, improving anaesthetic safety. Others turn to medication after surgery if weight regain occurs. Our page on weight loss injections after bariatric surgery covers the post-surgical use case specifically.

Safety profiles: what each approach asks of your body

The side-effect profile of GLP-1 injections is led by the gut: nausea, loose stools, constipation and indigestion are common, particularly after starting or increasing the dose, and most people find these settle within a couple of weeks. Pancreatitis is a less common but serious risk; the MHRA issued a Drug Safety Update in January 2026 reminding prescribers and patients to seek urgent help for severe stomach pain that reaches into the back. These medicines are not suitable during pregnancy, while breastfeeding, or when trying to conceive, and are not licensed for under-18s.

Surgical risks are different in character: bleeding, infection, anastomotic leak and venous thromboembolism are procedure-specific concerns, with a small but real mortality risk attached to any general anaesthetic. Long-term, nutrient deficiencies (particularly iron, B12 and vitamin D) require ongoing supplementation after most bariatric procedures. Neither route is risk-free. The question is always which risks are proportionate for your circumstances, a conversation with a clinical team, not a search result.

If you're considering the injection route and want to understand the full picture before deciding, our page covering the three main weight loss injections available is a good starting point. You can also read about how pills and injections compare if you're weighing up which format suits you, or explore oral and injectable formats if injections feel like a barrier.